Current Market Position and Price Movement
On 25 Nov 2025, Epigral’s stock price reached Rs.1400, the lowest level recorded in the past year. Despite this, the stock outperformed its sector by 0.9% on the day, indicating some relative resilience within its industry group. However, the share price remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend over multiple time frames.
In contrast, the broader market environment shows a more positive tone. The Sensex opened higher at 85,008.93 points, gaining 108.22 points (0.13%) before trading slightly lower at 84,964.83 points (0.08%). The index remains within 0.98% of its 52-week high of 85,801.70, supported by bullish moving averages where the 50-day moving average is positioned above the 200-day moving average. Mid-cap stocks are leading the market with the BSE Mid Cap index gaining 0.11% on the day.
Long-Term and Recent Performance Overview
Epigral’s one-year performance shows a decline of 28.18%, contrasting sharply with the Sensex’s positive return of 6.07% over the same period. The stock’s 52-week high was Rs.2195.85, highlighting the extent of the recent price contraction. Over the last three years, the stock has underperformed the BSE500 index, reflecting challenges in maintaining competitive growth and profitability.
Financially, the company’s operating profit has shown a negative compound annual growth rate of 5.49% over the past five years. This trend points to difficulties in expanding core earnings despite the company’s presence in the Specialty Chemicals sector, which is often characterised by cyclical demand and pricing pressures.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Recent Quarterly Financial Indicators
The latest quarterly results for Epigral reveal some areas of concern. Interest expenses for the most recent six-month period stand at Rs.45.21 crores, reflecting a growth rate of 286.41%. This sharp rise in interest costs may impact the company’s net profitability and cash flow management.
Profit after tax (PAT) for the quarter was Rs.51.22 crores, showing a decline of 52.6% compared to the average of the previous four quarters. Additionally, the operating profit margin to net sales ratio for the quarter was recorded at 22.53%, the lowest in recent periods, indicating margin pressures possibly due to cost escalations or pricing challenges.
Balance Sheet and Efficiency Metrics
Despite the pressures on profitability and share price, Epigral demonstrates strong management efficiency. The company’s return on capital employed (ROCE) stands at 23.19%, signalling effective utilisation of capital resources. Furthermore, the debt servicing capability appears robust, with a Debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels relative to earnings before interest, tax, depreciation, and amortisation.
Valuation metrics show a fair assessment with an enterprise value to capital employed ratio of 2.5. The stock is trading at a discount compared to the average historical valuations of its peers in the Specialty Chemicals sector. Over the past year, while the stock price has declined by 28.18%, the company’s profits have risen by 37.1%, resulting in a price/earnings to growth (PEG) ratio of 0.5, which reflects the relationship between earnings growth and valuation.
Epigral or something better? Our SwitchER feature analyzes this small-cap Specialty Chemicals stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Shareholding and Sector Context
Epigral operates within the Specialty Chemicals industry, a sector known for its technical complexity and sensitivity to raw material costs and regulatory environments. The company’s majority shareholding is held by promoters, which often provides stability in governance and strategic direction.
While the stock has faced downward pressure over the past year, the broader market and sector indices have shown relative strength. The Sensex’s proximity to its 52-week high and the mid-cap segment’s modest gains contrast with Epigral’s performance, underscoring the stock-specific factors influencing its valuation.
Summary of Key Financial Data
To recap, Epigral’s stock price at Rs.1400 marks a 52-week low, with a year-to-date return of -28.18%. The company’s operating profit has contracted at an annual rate of 5.49% over five years, while recent quarterly results show a 52.6% decline in PAT and a significant rise in interest expenses. Despite these challenges, the company maintains a strong ROCE of 23.19% and a manageable Debt to EBITDA ratio of 1.34 times. Valuation metrics indicate the stock trades at a discount relative to peers, with profits rising by 37.1% over the past year despite the share price decline.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
